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Aim To evaluate the influence of food habits, specifically 
adherence to the Mediterranean diet, on carotid intima-
media thickness (CIMT) and the presence of plaques in 
HIV-infected patients taking antiretroviral therapy (ART) 
and non-HIV-infected participants and to determine if HIV 
infection contributes independently to subclinical athero-
sclerosis.
Methods We conducted a cross-sectional study of 110 
HIV-infected patients on ART and 131 non-HIV-infected 
participants at the University Hospital for Infectious Dis-
eases in Zagreb, Croatia, from 2009-2011. CIMT measure-
ment and determination of carotid plaque presence was 
detected by ultrasound. Adherence to the Mediterranean 
diet was assessed by a 14-point food-item questionnaire. 
Subclinical atherosclerosis was defined by CIMT≥0.9 mm 
or ≥1 carotid plaque.
Results In HIV-infected patients, subclinical atherosclero-
sis was associated with older age (P < 0.001; Mann-Whitney 
test), higher body mass index (P = 0.051; Mann-Whitney 
test), hypertension (P < 0.001; χ2 test), and a lower Medi-
terranean diet score (P = 0.035; Mann-Whitney test), and 
in non-HIV-infected participants with older age (P < 0.001; 
Mann-Whitney test) and hypertension (P = 0.006; χ2 test). 
Multivariate analysis showed that decreased adherence to 
the Mediterranean diet was associated with higher odds 
of subclinical atherosclerosis (odds ratio [OR] 2.28, 95% 
confidence interval [CI] 1.10-4.72, P = 0.027) as was cur-
rent smoking (OR 2.86, 95% CI 1.28-6.40), hypertension (OR 
3.04, 95% CI 1.41-6.57), and male sex (OR 2.35, 95% CI 0.97-
5.70). There was a significant interaction of age and HIV sta-
tus, suggesting that older HIV-infected patients had higher 
odds of subclinical atherosclerosis than controls (OR 3.28, 
95% CI 1.24-8.71, P = 0.017 at the age of 60 years).
Conclusion We confirmed the association between lower 
adherence to the Mediterranean diet and increased risk of 
subclinical atherosclerosis and found that treated HIV in-
fection was a risk factor for subclinical atherosclerosis in 
older individuals.
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The advent of antiretroviral therapy (ART) for treatment 
of human immunodeficiency virus (HIV) infection has im-
proved the quality of life and life expectancy of HIV-infect-
ed patients (1,2). However, a number of comorbidities have 
emerged, including atherosclerosis (3,4).
The impact of HIV infection and exposure to ART on de-
velopment of subclinical atherosclerosis is incompletely 
understood (1,5). Several factors may contribute to an in-
creased risk of coronary and cerebrovascular artery disease 
in HIV-infected patients: chronic endothelial or myocardial 
inflammation due to HIV infection per se, dyslipidemia as-
sociated with ART, and the interaction of treatment with 
traditional risk factors for cardiovascular disease (smoking, 
hypertension, age, etc) (1). Also, several antiretroviral drugs 
are believed to be partially related to an increase in cho-
lesterol levels (6). The risk and problems associated with 
ART have led to the study of treatment-sparing strategies, 
which might provide the benefits of ART while minimizing 
the risk of adverse advents and other risks (7). The Strat-
egies for Management of Antiretroviral Therapy (SMART) 
trial was conducted to compare the episodic use of ART 
according to the CD4+ count with the current practice of 
continuous ART (7).
An early marker of atherosclerosis is an increase in carotid 
intima-media thickness (CIMT), which enables the risk as-
sessment of coronary and cerebral-artery disease (8). Ca-
rotid plaque area is another marker, which is more strongly 
associated with traditional risk factors and is more predic-
tive of myocardial infarction than of stroke (9,10). There 
are many studies on the association of HIV infection, HIV 
disease parameters, and ART use with subclinical carotid 
artery atherosclerosis, yet there is still controversy over 
whether chronic HIV infection and ART (mainly protease 
inhibitors, PI) contributes to subclinical atherosclerosis. Al-
though there are cross-sectional studies reporting an asso-
ciation between HIV infection, ART, and subclinical athero-
sclerosis (11-16), a number of studies did not find such an 
association (1,17-19).
The Mediterranean diet (20) has been shown to protect 
against cardiovascular disease and other chronic condi-
tions (21-23). However, only a few studies have investigat-
ed the relationship of dietary intake with body fat changes 
and metabolic abnormalities in HIV-infected patients (24-
26). To the best of our knowledge, the association between 
the adherence to Mediterranean diet and CIMT and the 
presence of plaques in HIV-infected patients taking ART 
has never been explored.
The aims of the present study are to evaluate the influence 
of food habits, specifically adherence to the Mediterranean 
diet, on CIMT and the presence of plaques in HIV-infect-
ed patients taking ART and non-HIV-infected participants 
and to assess if HIV-infection contributes independently to 
subclinical atherosclerosis.
MethodS
Study design
We conducted a cross-sectional study comparing CIMT 
and the presence of carotid plaques as surrogate markers 
of atherosclerosis in HIV-infected patients and non HIV-in-
fected participants.
Study population
We selected participants from a consecutive sample of HIV-
infected patients who had been on ART for ≥12 months at 
the University Hospital for Infectious Diseases (UHID) in Za-
greb, Croatia. Non HIV-infected participants were healthy 
volunteers who were UHID employees or individuals who 
came to the Department of Radiology and Ultrasound at 
UHID for routine preventive ultrasound check-ups. They 
were not tested for HIV before the study. Participants were 
consecutively recruited and enrolled over a 20-month peri-
od beginning in July 2009. Inclusion criteria for HIV-infected 
patients were age of over 18 years with documented HIV 
infection (enzyme immunoassay and Western-blot positive) 
and at least 12 months of ART, and for controls the age of 18 
years or older. Exclusion criteria were dementia, current acute 
illness, current use of drugs that modify lipid and glucose 
metabolism (insulin, metformin, glibenclamide, glimepiride, 
glyquidone, acarbose, rosiglitozone, pioglitazone, sitagliptin, 
vildagliptin, repaglinide, exenatide, liraglutide, simvastatin, 
fluvastatin, lovastatin, atrovastatin, rosuvastatin, gemfibro-
zil, fenofibrate, ezetimibe, omega-3 acids), as well as diuret-
ics and corticosteroids. We also excluded participants with 
a history of cardiovascular disease or stroke, documented 
hepatitis C infection, diabetes mellitus, and allergy or intoler-
ance to olive oil, fish, or nuts. All participants provided writ-
ten informed consent prior to enrolment. The study proto-
col was reviewed and approved by the Ethics Committee of 
UHID and the Committee on Human Research at the Uni-
versity of California, San Francisco.
Ultrasound measurements and definitions of outcomes
Participants were enrolled and underwent ultrasound 
measures at the same visit. Measurements of CIMT 
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and assessment of the plaque presence was performed by 
a single radiologist, who was blinded to the participants’ 
HIV status and Mediterranean diet score, using a linear ar-
ray probe (10 MHz and 42 mm) in the supine position. We 
examined the left and right common carotid arteries in an-
terolateral, posterolateral, and mediolateral directions and 
obtained longitudinal images of the distal common carot-
id arteries in which the interfaces were most clear. CIMT 
was measured in the far wall of the common carotid ar-
tery, 1 cm proximal to the carotid bulb in the region free 
of plaques with the optimum angle for measuring at the 
proximal and distal wall (27).
We defined plaque as a focal wall thickening 50% great-
er than the surrounding wall thickness, confirmed during 
scanning by electronic calipers (28). We examined the left 
and right carotid bifurcations and internal and common 
carotid arteries for the presence of plaque. Subclinical ath-
erosclerosis was defined as CIMT≥0.9 mm and/or the pres-
ence of ≥1 carotid plaque (10).
Nutritional and clinical assessment
Prior to the ultrasound, each participant was asked to fill 
out a 14-point food-item questionnaire to assess the ad-
herence to the traditional Mediterranean diet. The ques-
tionnaire was originally developed and validated by Babio 
et al (29,30) and was used to rapidly control for compliance 
with the dietary intervention of the Prevencion con Dieta 
Mediterranea (PREDIMED) study, a multicenter clinical trial 
aimed at assessing the effects of the traditional Mediterra-
nean diet on the primary prevention of cardiovascular dis-
ease (31). It was translated into Croatian, and completed 
during a face-to-face interview with the attending physi-
cian. From the questionnaire we derived the composite 
dietary score, dichotomized it at the median, and defined 
low adherence to the Mediterranean diet as a score of <4. 
We predefined the use of the median because of our rela-
tively small sample size.
We abstracted additional data for HIV-infected patients, in-
cluding medication history, from medical records using a 
standardized abstraction form. Patients were considered as 
having been treated with a particular drug or drug class if the 
drug combination had been administered for more than 12 
months. We measured the patients’ weight with a standard 
physician’s office balance scale and rounded the weight to 
the nearest 0.1 kg, and the height using a wall-mounted 
stadiometer and rounded the height to the nearest 0.1 
cm. Blood pressure measurements were obtained 
in a seated position (at the right upper arm), using a stan-
dard mercury sphygmomanometer, expressed in terms of 
the systolic pressure over diastolic pressure in millimeters of 
mercury (mmHg). Hypertension was defined according to 
the guidelines of the Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation and Treat-
ment of High Blood Pressure, that is, systolic blood pressure 
≥140mmHg or diastolic blood pressure ≥90mmHg and/or 
concomitant use of antihypertensive medications (32).
We categorized the cigarette smoking status as current or 
non-current smoker. Previous cardiovascular diseases (as 
an exclusion criterion) included history of angina, myo-
cardial infarction, coronary artery disease, atrial fibrillation, 
congestive heart failure, and valvular heart disease (28). 
Stroke was defined by the National Institute of Neurologi-
cal Disorders and Stroke Classification of Cerebrovascular 
Diseases III (28).
We determined plasma HIV viral load using COBAS Amplicor 
HIV-1 Monitor Test, version 1.5 (Roche Diagnostic Systems, 
Basel, Switzerland) with a lower limit detection of 50 cop-
ies per milliliter (ultrasensitive method). Absolute CD4 T-cell 
counts (in cells/µL) were measured using Flow Count Fluo-
rospheres (Beckman Coulter, Fullerton, CA, USA) and four-
color flow cytometry was performed using Cytomics FC500 
flow cytometer (Beckman Coulter, Fullerton, CA, USA).
Statistical analysis
Categorical variables are presented as proportions and 
non-normally distributed continuous variables as medians 
and interquartile ranges (IQR). The normality of distribution 
was assessed graphically and by the Shapiro-Wilk test. To 
compare different characteristics of participants with and 
without subclinical atherosclerosis, we used the Whitney-
Mann test for continuous variables and Fisher exact test or 
χ2 test for categorical variables, separately for HIV-infected 
participants and non HIV-infected participants. The odds 
of having subclinical atherosclerosis were calculated in 
crude logistic regression models, which included one in-
dependent variable (body mass index [BMI], sex, smoking, 
hypertension, Mediterranean diet score, or HIV status) and 
age and their interaction for the whole study population 
(N = 241). In multivariate logistic regression model analy-
sis, we included all the above mentioned variables except 
BMI (non-significant in crude analysis) and the interaction 
of age with HIV status. Statistical analyses were performed 
with SAS software, version 9.1.3. (SAS Institute, Cary, NC, 
USA). The level of statistical significance was set at P < 0.05.
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ReSULtS
We enrolled 110 HIV-infected patients and 131 non-HIV-
infected participants. All the participants were Caucasian. 
HIV-infected patients were more frequently male, younger, 
had a lower BMI, and a higher Mediterranean diet score 
(Table 1).
More than 50% of the 110 HIV-infected patients were on 
non-nucleoside reverse transcriptase inhibitors-contain-
ing antiretroviral regimens (Table 2). Of 110 patients, 106 
(96.4%) had an undetectable viral load (<50 copies per 
milliliter). Of 4 patients with detectable viral load, one had 
discontinued antiretroviral treatment and three had low-
level viremia (<1000 copies/mL). HIV-infected participants 
taking PI and those taking other antiretroviral regimens 
showed no differences in ultrasound-measured CIMT 
medians, CIMT≥0.9 mm, and ≥1 carotid plaque presence 
(P = 0.819, P = 0.791, and P = 0.904, respectively).
Subclinical atherosclerosis was found in 79 (32.6%) of 
241 participants (Table 3): 37 (33.6%) of 110 HIV-infected 
patients and 42 (32.1%) of 131 non HIV-infected partici-
pants. The proportion of men and women in HIV-infected 
and non-HIV-infected group with subclinical atheroscle-
rosis was not different (P = 0.08 and P = 0.632, respective-
ly). In HIV-infected patients, subclinical atherosclerosis 
was associated with older age (P < 0.001, Mann-Whitney 
test), higher BMI (P = 0.051; Mann-Whitney test), and hy-
pertension (P < 0.001; χ2 test). In non HIV-infected par-
ticipants, subclinical atherosclerosis was associated with 
older age (P < 0.001; Mann-Whitney test) and hyperten-
sion (P = 0.006; χ2 test). Patients with subclinical athero-
sclerosis had lower median Mediterranean diet scores. In 
non HIV-infected participants, 24 of 42 (57%) with sub-
clinical atherosclerosis and 42 of 89 (47%) without sub-
clinical atherosclerosis had a Mediterranean diet score <4 
(P = 0.288; χ2 test). In HIV-infected participants, 17 of 37 
(46%) with subclinical atherosclerosis and 18 of 73 (25%) 
without subclinical atherosclerosis had a Mediterranean 
diet score <4 (P = 0.024; χ2 test). Among participants >45 
years old, more HIV-infected patients than non-HIV-in-
fected participants had subclinical atherosclerosis (56% 
vs 40%, P  = 0.042).
taBLe 1. Characteristics of hIV-infected (n = 110) and non-hIV-infected participants (n = 131) examined by ultrasound to detect 
subclinical atherosclerosis
hIV-infected 
patients (n = 110)
non hIV-infected 
patients (n = 131) P
Male sex (n, %)  93 (84.5)  91 (69.5)  0.006*
Age, years (median, range‡)  46.5 (40-56)  52 (45-61)  0.003†
Weight, kg (median, range)  78 (70-84)  85 (73-98) <0.001†
Body mass index, kg/m2˛ (median, range)  24.8 (22.5-26.4)  27.8 (24.5-30.8) <0.001†
Mediterranean diet score (median, range)   5 (3-7)   3 (2-5) <0.001†
Carotid intima-media thickness, right, in millimeters (median, range)   0.67 (0.53-0.82)   0.68 (0.61-0.82)  0.640†
Carotid intima-media thickness, left, in millimeters (median, range)   0.68 (0.61-0.83)   0.72 (0.58-0.83)  0.591†
Systolic blood pressure in mmHg (median, range) 130 (120-140) 130 (120-140)  0.436†
Participants with hypertension (n, %)  31 (28.1)  29 (22.1)  0.240*
Current smoker (n, %)  40 (36.4)  30 (22.9)  0.022*
Carotid intima-media thickness ≥0.9 mm (n, %)  31 (28.2)  25 (19.1)  0.095*
Presence of ≥1 carotid plaque (n, %)  26 (23.6)  31 (23.7)  0.996*
Presence of ultrasound-assessed subclinical atherosclerosis (n, %)  37 (33.6)  42 (32.1)  0.795*
*χ2 test.
†Mann-Whitney test.
taBLe 2. duration of antiretroviral therapy (aRt), currently 
used aRt, current plasma hIV-1 viral load, and Cd4 cell counts 
in hIV-infected patients (n = 110) at the time of ultrasound 
measurement of carotid intima-media thickness (CIMt) and 
the presence of plaque
duration of aRt in years (n, %)   5.1 (2.6-8.4)
duration of exposure to protease inhibitors 
(years) (n, %)
  3.8 (1.5-6.5)
aRt combination (n, %):
two nucleoside or nucleotide reverse transcriptase 
inhibitors plus one non-nucleoside reverse tran-
scriptase inhibitor
 73 (66.4)
two nucleoside or nucleotide reverse transcriptase 
inhibitors plus one protease inhibitor
 28 (25.5)
other, including entry inhibitor or integrase inhibitor   9 (8.1)
Current Cd4 cell count in cells/µL (median, range)467 (311-584)
hIV RNa≥50 copies/mL (n, %)   4 (3.6)
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When the whole study population was analyzed using one 
independent variable and age in the crude analysis mod-
el, subclinical atherosclerosis was associated with current 
smoking, male sex, and hypertension (Table 4). In multi-
variate analysis, subclinical atherosclerosis remained asso-
ciated with all risk factors including lower adherence to the 
Mediterranean diet (Mediterranean diet score <4) (odds ra-
tio 2.28; 95% confidence interval 1.10-4.72; P = 0.027) (Ta-
ble 4). There was a significant interaction of age and HIV 
status in both crude (P = 0.028) and multivariate analysis 
(P = 0.029), suggesting that the probability of having sub-
clinical atherosclerosis increased in HIV-infected patients 
after the age of 45 years more rapidly than in non-HIV-in-
fected individuals (Figure 1).
dISCUSSIoN
We found that subclinical atherosclerosis was common 
both among HIV-infected and non-HIV-infected partici-
pants and was associated with older age, male sex, current 
smoking, and hypertension. Lower Mediterranean diet 
scores were associated with higher odds of subclinical ath-
erosclerosis. Older HIV-infected patients treated with ART 
were more likely to have subclinical atherosclerosis than 
non HIV-infected individuals.
Croatians living near the Adriatic Sea have a relatively low-
er occurrence of chronic diseases such as cancer, diabetes, 
obesity, and cardiovascular diseases than Croatians living 
taBLe 3. Ultrasound-assessed subclinical atherosclerosis of hIV-infected (n = 110) and non-hIV-infected participants (n = 131) by 
demographic characteristics and adherence to Mediterranean diet scores
hIV-infected patients with 
subclinical atherosclerosis 
(n = 110)
Non hIV-infected participants 
with subclinical atherosclerosis
(n = 131)
Variable yes (n = 37) no (n = 73) P yes (n = 42) no (n = 89) P
Age in years (median, range)‡  58 (53-65)  42 (37-47) <0.001*  59.5 (52-65)  50 (42-56) <0.001*
Body mass index (median, range)  25.3 (24.3-26.4)  24 (22.1-26.4)  0.051*  28.1 (24.5-32.1)  27.7 (24.5-30.4)  0.407*
Systolic blood pressure in mmHg (median, range) 140 (120-150) 120 (115-130) <0.001* 140 (130-150) 125(120-135) <0.001*
Hypertension (n, %)  19 (51.4)  13 (17.9) <0.001†  15 (35.7)  13 (14.6)  0.006†
Mediterranean diet score (median, range)   4 (3-6)   6 (4-7)  0.035*   3 (3-5)   4 (2-5)  0.692*
*Mann-Whitney test.
†χ2 test.
taBLe 4. Crude and adjusted odds of subclinical atherosclerosis by patient characteristics and Mediterranean diet score in hIV-
infected (n = 110) and non-hIV-infected (n = 131) participants
Crude analysis* Multivariate analysis†
odds ratio (95% confidence interval) P odds ratio (95% confidence interval) P
Mediterranean diet Score:
<4 1.83 (0.96-3.48)  0.065 2.28 (1.10-4.72) 0.027
≥4 1 1
Current smoker:
yes 2.65 (1.26-5.54)  0.010 2.86 (1.28-6.40) 0.010
no 1 1
Sex:
male 2.80 (1.23-6.36)  0.014 2.35 (0.97-5.70) 0.058
female 1 1
hIV- status at the age of 60 y:
HIV-infected 3.74 (1.50-9.31)  0.005 3.28 (1.24-8.71) 0.017
HIV non-infected 1 1
hypertension:
yes 3.72 (1.81-7.67) <0.001 3.04 (1.41-6.57) 0.005
no 1 1
*adjusted for age and one characteristic.
†adjusted for age, Mediterranean diet Score, current smoking status, sex, hIV-status, and hypertension.
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in the continental area, which has been linked to adher-
ence to the Mediterranean diet (33). Although it is hard to 
define what exactly constitutes the Mediterranean diet as 
there are as many Mediterranean eating patterns as there 
are Mediterranean countries (33), the main staples always 
include olive oil, fish, and red wine.
The questionnaire used in our study was a slightly modified 
questionnaire previously validated in Spain, which is suit-
able to assess the nutritional habits of the Croatian popula-
tion living in the Mediterranean region (29,34,35). This brief 
14-item questionnaire is less time-demanding, less expen-
sive, and requires less collaboration from participants than 
the usual full-length food frequency questionnaires or oth-
er more comprehensive methods (31). In addition, it allows 
the possibility of providing feedback to the participant im-
mediately upon completion. It was the key element in the 
PREDIMED trial and had been previously validated against 
food frequency questionnaires used in the study (23). Full-
length food frequency questionnaires usually used 100 
items, 24-hour recalls, or other time-consuming methods, 
to evaluate adherence to the Mediterranean dietary pat-
tern. In contrast to these methods, the brief tool assessing 
only a small number of foods measured in servings/d or 
servings/week enables physicians and participants to ne-
gotiate changes in patients’ dietary quality and set goals in 
easily understandable units (food servings) (31).
In a previous observational study conducted in Croatia, 
no association was found between plasma lipid changes 
during the first year of ART and adherence to the Medi-
terranean diet (20). This association was also not observed 
in non-HIV-infected populations (36). In the multivariate 
model of our study, low adherence to the Mediterranean 
diet was, however, significantly associated with subclinical 
atherosclerosis. It is possible that there is a synergy among 
the nutrient-rich components included in the Mediterra-
nean diet that fosters favorable changes in the intermedi-
ate pathways of cardiometabolic risk (23).
To determine cardiovascular risk among HIV-infected per-
sons, we used surrogate markers of subclinical atheroscle-
rosis: ultrasound-measured CIMT and the presence of ≥1 
plaque. Higher levels of CIMT have been found to predict 
serious adverse cardiovascular events (30). Greater CIMT 
than in controls (0.004 mm) has also been associated with 
HIV infection in a meta-analysis of 13 cross-sectional stud-
ies (37,38). However, a significant difference in CIMT and 
plaque prevalence between HIV-infected patients and 
non-HIV infected participants has not been found (1,18,19). 
One of the possible explanations for controversial results is 
the limited ability of anatomic imaging to comprehensive-
ly define the cardiovascular risk (38). We found more sub-
clinical atherosclerosis cases in HIV-infected patients than 
in non HIV-infected controls after the age of 45 years.
The SMART trial found a higher risk of cardiovascular 
events among patients with discontinuation of ART than 
in patients with uninterrupted ART (7). This suggests an 
impact of HIV infection on cardiovascular events, possibly 
mediated through inflammation and thrombosis induced 
by HIV (39).
It is quite possible that traditional cardiovascular risk fac-
tors are more important predictors of atherosclerosis than 
measurable HIV-related factors. In our HIV-infected partici-
pants, the factors significantly associated with subclinical 
atherosclerosis were smoking and hypertension. Smoking 
is common in HIV-infected patients and the Data Collec-
tion on Adverse events of Anti-HIV Drugs study found that 
smoking was the most powerful predictor of cardiovascu-
lar diseases (40).
Previous studies have suggested that there may be an 
association between the use of PI and increased CIMT 
(30,41). One quarter of HIV-infected participants in our 
study were on PI regimens for at least 12 months. We did 
not find any difference in surrogate markers of athero-
sclerosis between patients who were on a PI regimen 
and those who were not. However, we cannot rule 
FIGURe 1. estimated probability of subclinical atherosclerosis 
according to hIV status and age
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out this possibility due to the small sample size. Therefore, 
a longitudinal follow-up on our participants is planned to 
determine if HIV infection or PI therapy is important in the 
progression of subclinical atherosclerosis.
Our study has some important limitations. First, we utilized 
a cross-sectional design to determine the risk factors, CIMT, 
and plaque levels. Given the fact that the effects of HIV 
and ART on cardiovascular risk factors, such as cholesterol, 
high-density lipoproteins, and blood pressure are dynamic 
and cumulative, a longitudinal follow up would be better 
suited. Second, we did not measure biochemical corre-
lates of atherosclerosis, such as total cholesterol, high-den-
sity lipoproteins and low-density lipoproteins, which could 
potentially have provided additional evidence of the pro-
tective effect of the Mediterranean diet. Finally, non HIV-
infected participants should ideally have been identical to 
infected patients except for the presence of HIV-infection, 
but given the highly specialized nature of our institution, 
it was not possible to precisely match infected and non-
infected patients.
Our study demonstrated an association of subclinical ath-
erosclerosis with specific and traditional dietary habits, 
which had been associated with decreased all-cause mor-
tality and improvement in cardiovascular risk factors in pri-
or studies in the general population. We also provided evi-
dence that HIV infection treated with ART was associated 
with accelerated atherosclerosis in older individuals. These 
results should be considered in clinical assessment of car-
diovascular risk in HIV-infected patients.
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